A 68-year-old postmenopausal woman presents with acute onset severe back pain after a minor fall while gardening. On examination, she has kyphosis and loss of height compared to her medical records from 5 years ago. X-ray of the thoracic spine shows a wedge-shaped compression fracture at T7 with 40% loss of vertebral body height. Her serum calcium is 8.8 mg/dL, phosphate 3.5 mg/dL, and alkaline phosphatase is normal. DEXA scan shows a T-score of −3.2 at the lumbar spine. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Diagnosis This patient presents with **osteoporotic vertebral compression fracture** (wedge-shaped, 40% height loss) in a postmenopausal woman with T-score ≤ −3.0 (severe osteoporosis) and normal biochemistry (ruling out secondary causes). ## Management Rationale **Key Point:** Postmenopausal osteoporosis with fragility fracture requires pharmacological therapy, not lifestyle measures alone. ### Why Alendronate (Option 2) is Correct 1. **Bisphosphonate as first-line**: Alendronate is the gold-standard first-line agent for postmenopausal osteoporosis with fracture history [cite:Robbins 10e Ch 26]. 2. **Evidence base**: Alendronate reduces vertebral fracture risk by ~47% and hip fracture risk by ~50% in RCTs. 3. **Adequate supplementation**: Combined with calcium 1000 mg/day and vitamin D 800–1000 IU/day to ensure substrate availability and reduce secondary hyperparathyroidism. 4. **Cost-effectiveness**: Oral bisphosphonate is affordable and widely available in India. ### Mechanism of Alendronate Alendronate inhibits osteoclast-mediated bone resorption by: - Blocking farnesyl pyrophosphate synthase in the mevalonate pathway - Inducing osteoclast apoptosis - Reducing bone turnover (antiresorptive effect) **Clinical Pearl:** Bisphosphonates are **antiresorptive** agents (slow bone loss); they do NOT build new bone. Teriparatide (anabolic) is reserved for severe cases or bisphosphonate failure. ## High-Yield Management Algorithm ```mermaid flowchart TD A[Postmenopausal woman with osteoporosis]:::outcome A --> B{Fragility fracture present?}:::decision B -->|Yes| C[Bisphosphonate + Ca + Vit D]:::action B -->|No, T-score ≤ -2.5| D[Bisphosphonate + Ca + Vit D]:::action C --> E{Response adequate at 2 years?}:::decision D --> E E -->|Yes| F[Continue therapy]:::action E -->|No| G[Switch to Teriparatide or Denosumab]:::action G --> H[Anabolic or alternative agent]:::outcome ``` ## Dosing & Administration | Agent | Dose | Route | Frequency | Key Caution | |-------|------|-------|-----------|-------------| | Alendronate | 70 mg | PO | Weekly | Upright posture × 30 min; empty stomach | | Calcium | 1000 mg/day | PO | Divided | Separate from bisphosphonate by ≥2 hrs | | Vitamin D | 800–1000 IU | PO | Daily | Monitor 25(OH)D; target >20 ng/mL | **Warning:** Do NOT give calcium or iron supplements within 2 hours of alendronate — they reduce absorption to <10%. ## Why Other Options Are Incorrect - **Option 1 (Calcium + Vit D alone)**: Insufficient for a patient with T-score −3.2 and active fracture. Lifestyle and supplementation alone reduce fracture risk by only ~10–15%; pharmacotherapy is mandatory. - **Option 3 (HRT)**: Estrogen is no longer first-line due to increased cardiovascular and breast cancer risk (WHI trial). Reserved only if menopausal symptoms coexist and fracture risk is mild. - **Option 4 (Teriparatide)**: Anabolic agent; reserved for severe osteoporosis unresponsive to bisphosphonates or for patients with multiple fractures despite prior therapy. Not first-line due to cost and subcutaneous administration. **High-Yield:** Alendronate is the **most cost-effective and evidence-backed first-line agent** for postmenopausal osteoporosis in India.